Sickle Cell Disease News and Research

Latest Sickle Cell Disease News and Research

Baxter International acquires drug candidate developed to treat sickle cell disease

Baxter International acquires drug candidate developed to treat sickle cell disease

Bone marrow transplantation shows promising results among patients with severe sickle cell disease

Bone marrow transplantation shows promising results among patients with severe sickle cell disease

Children's Hospital Los Angeles ranked among nation's top 5 again

Children's Hospital Los Angeles ranked among nation's top 5 again

CIRM grants $5.6 million to develop HIV/AIDS therapeutic using Sangamo's ZFN genome-editing technology

CIRM grants $5.6 million to develop HIV/AIDS therapeutic using Sangamo's ZFN genome-editing technology

Immucor's PreciseType HEA test receives FDA approval to predict blood compatibility

Immucor's PreciseType HEA test receives FDA approval to predict blood compatibility

Acceleron, Celgene to give oral presentations on beta-thalassemia, myelodysplastic syndromes at EHA meeting

Acceleron, Celgene to give oral presentations on beta-thalassemia, myelodysplastic syndromes at EHA meeting

Eli and Edythe Broad Foundation gift $4 million to support UCLA research

Eli and Edythe Broad Foundation gift $4 million to support UCLA research

Highly advanced imaging method helps to monitor rapid changes in glutathione redox potentials in live cells

Highly advanced imaging method helps to monitor rapid changes in glutathione redox potentials in live cells

Scientists design new system for molecular blood group typing

Scientists design new system for molecular blood group typing

Mast Therapeutics reports net loss of $5.7 million for fourth quarter 2013

Mast Therapeutics reports net loss of $5.7 million for fourth quarter 2013

Low levels of oxygen, nitric oxide appear to have unfortunate synergy for patients with sickle cell disease

Low levels of oxygen, nitric oxide appear to have unfortunate synergy for patients with sickle cell disease

Emmaus reports preliminary top-line results from Phase 3 clinical trial for treatment of sickle cell disease

Emmaus reports preliminary top-line results from Phase 3 clinical trial for treatment of sickle cell disease

ATS develops clinical practice guidelines to help clinicians identify, manage patients with sickle cell disease

ATS develops clinical practice guidelines to help clinicians identify, manage patients with sickle cell disease

PCORI to award $7 million contract to Chicago coalition to establish clinical data research network

PCORI to award $7 million contract to Chicago coalition to establish clinical data research network

CIBMTR recognizes SCCA's Fred Hutchinson Bone Marrow Transplant Program

CIBMTR recognizes SCCA's Fred Hutchinson Bone Marrow Transplant Program

Parents and doctors must be aware and prepared to treat strokes in children

Parents and doctors must be aware and prepared to treat strokes in children

Stroke hospitalization and death rates associated with weather changes

Stroke hospitalization and death rates associated with weather changes

New drug helps children and young adults who have severe pain from sickle cell disease

New drug helps children and young adults who have severe pain from sickle cell disease

Biogen Idec, Sangamo BioSciences partner to develop therapeutics for hemoglobinopathies

Biogen Idec, Sangamo BioSciences partner to develop therapeutics for hemoglobinopathies

Emmaus completes all patient visits for Phase 3 trial of L-glutamine for treatment of sickle cell disease

Emmaus completes all patient visits for Phase 3 trial of L-glutamine for treatment of sickle cell disease

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.